ARDELYX, INC.ARDXEarnings & Financial Report
Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.
ARDX Q1 FY2026 Key Financial Metrics
Revenue
$94.5M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$-37.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-39.8%
YoY Growth
27.5%
EPS
$-0.15
ARDELYX, INC. Q1 FY2026 Financial Summary
ARDELYX, INC. reported revenue of $94.5M (up 27.5% YoY) for Q1 FY2026, with a net profit of $-37.6M (-39.8% margin).
Key Financial Metrics
| Total Revenue | $94.5M |
|---|---|
| Net Profit | $-37.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2026 |
Revenue Breakdown
ARDELYX, INC. Q1 FY2026 revenue of $94.5M breaks down across 4 segments, led by IBSRELA at $70.1M (74.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| IBSRELA | $70.1M | 74.2% |
| XPHOZAH | $23.3M | 24.7% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 0.7% |
| Product supply revenue | $354.0K | 0.4% |
ARDELYX, INC. Annual Revenue by Year
ARDELYX, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $407.3M).
ARDELYX, INC. Quarterly Revenue & Net Profit History
ARDELYX, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $94.5M | +27.5% | $-37.6M | -39.8% |
| Q4 FY2025 | $125.2M | +7.8% | $-407.0K | -0.3% |
| Q3 FY2025 | $110.3M | +12.3% | $-969.0K | -0.9% |
| Q2 FY2025 | $97.7M | +33.4% | $-19.1M | -19.5% |
| Q1 FY2025 | $74.1M | +61.0% | $-41.1M | -55.5% |
| Q4 FY2024 | $116.1M | +237.9% | $4.6M | 4.0% |
| Q3 FY2024 | $98.2M | +74.2% | $-809.0K | -0.8% |
| Q2 FY2024 | $73.2M | +227.9% | $-16.5M | -22.5% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73.2M | $98.2M | $116.1M | $74.1M | $97.7M | $110.3M | $125.2M | $94.5M |
| YoY Growth | 227.9% | 74.2% | 237.9% | 61.0% | 33.4% | 12.3% | 7.8% | 27.5% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $343.5M | $367.9M | $435.8M | $410.2M | $466.8M | $486.2M | $501.6M | $504.5M |
| Liabilities | $196.5M | $209.6M | $262.5M | $264.5M | $327.2M | $331.9M | $334.7M | $355.9M |
| Equity | $147.0M | $158.3M | $173.3M | $145.7M | $139.5M | $154.3M | $166.9M | $148.6M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-19.4M | $501000 | $9.8M | $-38.5M | $-25.3M | $365000 | $21.0M |